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Abstract Macrophages play a major role in angiogenesis. We
recently reported that oncostatin M (OSM), a cytokine of the
interleukin (IL)-6 family secreted by macrophages, has a potent
angiogenic activity on human microvascular endothelial cells
(HMEC-1), but has no effect on macrovascular cells (human
umbilical vein endothelial cells (HUVECs)). In this work, we
show that in HMEC-1, OSM (0.5^2.5 ng/ml), leukemia
inhibitory factor (LIF) (25 ng/ml), bFGF (25 ng/ml) and IL-1L
(5 ng/ml) induced production of cyclooxygenase (COX)-2. In
contrast, in HUVECs, neither OSM nor LIF induced COX-2
mRNA, suggesting that COX-2 might be implicated in the
angiogenic activity of OSM. This was confirmed by the
inhibiting effect on OSM-induced HMEC-1 proliferation of
specific COX-2 inhibitors. In vivo studies confirmed this findings.
We conclude that induction of COX-2 by OSM is necessary for
its angiogenic activity, but is not sufficient since IL-1L, which
also induces COX-2 in HMEC-1, has only a poor proliferative
effect.
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1. Introduction
Macrophages are prominent cellular components of athero-
sclerotic plaques. Cytokines secreted by activated macro-
phages are involved in the pathogenesis of atherosclerotic
plaque development and plaque rupture, which is responsible
for the acute ischemic syndrome. Among these cytokines, we
have previously suggested that oncostatin M (OSM), a cyto-
kine produced by activated monocytes/macrophages, could
play a major role in the development and complication of
atherosclerosis [1]. This may explain the results of epidemio-
logic studies showing that ¢brinogen is an important marker
of cardiovascular disease. This deterious role of OSM is sup-
ported by the observation that OSM was identi¢ed in the
atherosclerotic plaque [2].
Because the neovasculature of the plaque contributes to its
fragilization, we were interested in analyzing the e¡ect of
OSM on angiogenesis. We have previously shown that
OSM, and to a lesser extent leukemia inhibitory factor (LIF),
induces a potent proliferative e¡ect on microvascular cells
(human microvascular endothelial cells (HMEC-1)) and a
strong angiogenic activity both in in vitro and in vivo models.
Interestingly, the e¡ect of OSM was limited to microvascular
cells, since OSM did not induce any proliferative e¡ect in
endothelial cells (ECs) from the human macrovasculature (hu-
man umbilical vein endothelial cells (HUVECs)) [3]. The
mechanisms responsible for this angiogenic e¡ect have not
been elucidated. The e¡ect seems to be direct, as other known
angiogenic factors were not signi¢cantly increased by OSM.
Cyclooxygenase (COX, prostaglandin (PG)-endoperoxide
synthase) converts arachidonic acid to PG H2, which is then
metabolized by other enzymes to various PGs, including pros-
tacyclin and thromboxane. COX exists in, at least, two iso-
forms with a similar molecular weight (70^72 kDa). COX-1 is
expressed constitutively in various tissues. In contrast, the
expression of COX-2 is induced or up-regulated by mitogens,
cytokines or tumor promoters [4].
Since COX-2 has been implicated in angiogenesis [5,6], we
analyzed in this work the expression of COX-2 by ECs and its
possible contribution to OSM-induced angiogenic activity. To
that end, we investigated the e¡ect of OSM on COX-2 ex-
pression in ECs (HMEC-1 and HUVECs). We also studied
the e¡ect of COX inhibitors on microvascular EC prolifera-
tion and migration in vitro and on OSM-induced angiogenesis
in the in vivo rabbit cornea model [7].
2. Material and methods
2.1. Cytokines
Recombinant human OSM, LIF, bFGF and interleukin (IL)-1L
were supplied from RpD Systems (Minneapolis, MN, USA). Re-
combinant human IL-6 was a generous gift of Sandoz (Basel, Switzer-
land). Antibody against COX-2, indomethacin, ibuprofen and NS-398
were obtained from TEBU (Le Perray-en-Yvelines, France).
2.2. Cell culture
The HMEC-1 cell line was provided by Dr Ades (Center for Dis-
ease Control and Prevention, Atlanta, GA, USA), who established
this cell line by transfecting human dermal ECs with SV40 A gene
product and large T-antigen [8]. HMEC-1 cells were cultured in
MCDB131 medium (Sigma, St. Louis, MO, USA) supplemented
with 15% FCS, 100 IU/ml penicillin, 100 Wg/ml streptomycin, 10 ng/
ml epidermal growth factor (EGF) (Euromedex, Sou¡elweyersheim,
France) and 1 mg/ml hydrocortisone (Pharmacia-Upjohn, Saint Quen-
tin en Yvelines, France).
HUVECs, collected as described by Ja¡e et al. [9], were cultured
under similar conditions as HMEC-1 but the percentage of FCS was
lower (8%).
0014-5793 / 99 / $20.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 1 3 0 1 - 0
*Corresponding author. Fax: (33) (2) 35 14 83 40.
Abbreviations: OSM, oncostatin M; LIF, leukemia inhibitory factor;
IL, interleukin; COX, cyclooxygenase; EC, endothelial cell
FEBS 22740 6-10-99
FEBS 22740 FEBS Letters 459 (1999) 453^457
2.3. Cell proliferation assay
For the proliferation assay, EGF was omitted and we used the
minimal concentration of FCS allowing for su⁄cient viability of the
cells (7.5%). Brie£y, after trypsinization, the cells were seeded at a
concentration of 50U103 cells per well in a 24-well plate (Nunc, Ros-
kilde, Denmark) and incubated with the cytokines. The medium was
changed every 2 days and the cell number was measured at day 5 by
counting the cells in a particle counter (Coulter Z1, Coultronics, Mar-
gency, France) after detachment by trypsin (0.05%, w/v, Sigma).
2.4. Chemotaxis assay
HMEC-1 cells were detached with EDTA 0.5 mM, washed twice in
phosphate-bu¡ered saline (PBS) and resuspended in MCDB131 with
0.2 mg/ml bovine serum albumin (BSA, Sigma). Fifty thousand cells
were seeded in the upper chamber of a Transwell insert (PTFE mem-
brane with 8 Wm diameter pores, Dutcher, Brumath, France). The
lower chamber was ¢lled with 1 ml of MCDB131 with 2 mg/ml
BSA and the cytokine to be tested. In order to test the e¡ect of a
COX-2 inhibitor on cytokine-induced chemotaxis, NS-398 was added
to the upper chamber at a ¢nal concentration of 50 WM. After 24 h,
migrated cells were scraped from the lower surface of the membrane
with a cell scraper (Nunc) and then suspended in the medium of the
lower chamber to count all migrating cells (both adherent and cells in
suspension). These cells were counted with a hemocytometer (Coulter
Z1, Coultronics).
2.5. Total RNA extraction
Cells were incubated in a 6-well plate (Nunc) until con£uent and
then incubated for 3 or 24 h with the cytokines. Cells were then
detached with 0.05% trypsin and washed twice in Dulbecco’s PBS.
Total RNA extraction was performed using the SV total RNA iso-
lation system (Promega, Madison, WI, USA) according to the man-
ufacturer’s instructions.
2.6. Reverse transcriptase-polymerase chain reaction (RT-PCR) assay
Oligonucleotide primers (which £ank intron DNA) HSCOX2-S
(5P-CCGGACAGGATTCTATGGAGA-3P sense bases 232^252)
and HSCOX2-AS (5P-CAATCATCAGGCACAGGAGG-3P antisense
bases 531^512) were used in a RT-PCR assay. For each reaction
(volume of 50 Wl), the mixture containing 0.4 pg of total RNA, 50
pmol of each primer, 0.2 WM dNTPs, 1 mM MgSO4, 5 Wl of 10X
AMV/T£ reaction bu¡er was prepared and heated for 2 min at 94‡C.
When the temperature was decreased to 48‡C, 2 U AMV and 2 U T£
enzymes were added to the reaction mixtures. The reverse transcrip-
tion was performed at 48‡C for 50 min. The reaction products were
then subjected to 30 cycles of PCR: 94‡C for 2 min, 60‡C for 30 s and
68‡C for 1 min, followed by 29 cycles of 94‡C for 1 min, 60‡C for 30 s
and 68‡C for 1 min and ¢nally, 68‡C for 7 min.
RT-PCR ampli¢cation of L-actin (5P-ATCTGGCACCACACCTT-
CTACAATGAGCTGCG-3P sense primer; 5P-CGTCATACTCCTG-
CTTGCTGATCCACATCTGC-3P antisense primer) was performed
as control under the same conditions as above. The COX-2 (300 bp)
and the L-actin (838 bp) mRNA ampli¢cation products were analyzed
in agarose gel (1.5%) electrophoresis using ethidium bromide staining.
2.7. Western blot analysis
Cells cultured in six well plates were incubated with IL-1L (5 ng/ml)
or OSM (0.5, 1 and 2.5 ng/ml) for 24 h. Cells were washed in PBS,
trypsinized and resuspended in lysis bu¡er RIPA (10 mM Tris-HCl,
1% sodium desoxycholate, 1% Nonidet P-40, 150 mM NaCl, 0.1%
sodium dodecyl sulfate (SDS), pH 7.5) containing one tablet per ml
protease inhibitor mixture (Boehringer Mannheim, Roche diagnostic,
Meylan, France) for 30 min on ice. Cell lysate was collected by cen-
trifugation at 12 000 rpm at 4‡C and the amount of protein was
determined by the method of Bradford [10].
Eighty pg of protein per lane for each sample was run in a 10%
SDS-polyacrylamide gel before transfer onto a nitrocellulose mem-
brane (Amersham, Courtaboeuf, France). The mnembrane was incu-
bated in blocking bu¡er (10 mM Tris-HCl, 100 mM NaCl, 0.05%
Tween-20 and 5% fat-free milk, pH 7.5) for 2 h, then incubated for
l h in a goat IgG against human COX-2 (TEBU) at a ¢nal concen-
tration of 0.5 pg/ml. The membrane was washed three times in Tris-
Tween-20 bu¡er and incubated for another hour with horseradish
peroxidase-conjugated rabbit anti-goat IgG serum (Biosys, Com-
piegne, France). After washing, COX-2 was detected using a Luminol
ECL detecting kit (Amersham).
2.8. In vivo angiogenesis assay
Adult New-Zealand white rabbits (Charles River, St. Aubin-les-El-
beuf, France) weighing 1.5^2 kg were anesthetized with ketamine,
(Ketalar 25 mg/kg intraperitoneally, Parke Davis, Courbevoie,
France). The eyes were topically anesthetized with oxybuprocaine
(Cibe¤sine, Laboratoire Chauvin, France) and the globes were prop-
tosed with jeweler forceps. Using an operating microscope, a central,
intrastromal linear keratotomy was performed with a surgical blade.
A lamellar micropocket was then dissected and was extended to with-
in 2 mm of the superior limbus. Beforehand, dehydrated (1U2 mm)
pellets made of 70% hydratable hydrogel were imbibed with vehicle
only (sterile water, Eurobio) or 100 ng/implant of OSM and placed
into the preformed corneal pocket. To test the e¡ect of a COX in-
hibitor on OSM-induced angiogenesis, rabbit eyes received two drops
of £urbiprofen 0.03% (Ocufen, Allergan, Mougins, France) three
times a day during the period of the test.
The eyes were routinely examined by slit lamp biomicroscopy on
postoperative day 8 after implantation. Rabbits were anesthetized
with ketamine and the eyes were proptosed. Photographs were
made and the area of neovascularization was evaluated and scored:
0 = absence of neovascularization, 1 = area of neovascularization6 2
mm2, 2 = area of neovascularization between 2 and 4 mm2, 3 = area of
neovascularizationv4 mm2. The studies have been carried out in ac-
cordance with the Guide for the Care and Use of Laboratory Ani-
mals. In order to analyze whether the e¡ect of cytokines on angio-
genesis is direct or due to in¢ltration by in£ammatory cells,
histological studies were performed on sections after hematoxylin-
eosin staining.
2.9. Statistical analysis
Signi¢cant values were determined using a two-tailed non-paramet-
ric Mann-Whitney test using the InStat software (Sigma). The results
are expressed as mean value þ S.E.M. P6 0.05 was considered as sig-
ni¢cant.
3. Results
3.1. Induction of COX-2 mRNA in HMEC-1 by OSM
The e¡ect of OSM was ¢rst studied on COX-2 mRNA
levels. Cells were incubated with increasing concentrations
of OSM or 5 ng/ml of IL-1L, which is known to be a potent
inducer of expression of COX-2 mRNA in various cell types.
A concentration-dependent increase in COX-2 mRNA expres-
Fig. 1. E¡ects of OSM, IL-6, LIF or IL-1L on COX-2 mRNA and
protein expression. (A) COX-2 and L-actin mRNA expression after
a 3 h incubation. 1: control, 2: IL-1L 5 ng/ml, 3: OSM 0.5 ng/ml,
4: OSM 1 ng/ml, 5: OSM 2.5 ng/ml. (B) COX-2 and L-actin
mRNA expression after a 24 h incubation. 1: control, 2: IL-1L
5 ng/ml, 3: OSM 0.5 ng/ml, 4: OSM 1 ng/ml, 5: OSM 2.5 ng/ml.
(C) COX-2 and L-actin mRNA expression after a 3 h incubation.
1: control, 2: LIF 25 ng/ml, 3: IL-6 10 ng/ml, 4: bFGF 25 ng/ml.
(D) Western blot of COX-2 protein expression in HMEC-1. 1: OSM
2.5 ng/ml, 2: IL-1L 5 ng/ml, 3: control.
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sion in response to OSM occurred after 3 h (Fig. 1A). How-
ever, IL-1L induces a more potent increase. The fact that a
RT-PCR assay reveals COX-2 mRNA in control HMEC-1
could be due to the culture conditions. After a 24 h incuba-
tion, Fig. 1B shows a persistent concentration-dependent in-
crease in COX-2 mRNA expression. LIF (25 ng/ml) and
bFGF (25 ng/ml) also induced an increase in COX-2
mRNA expression after a 3 h incubation, while IL-6 did
not modify COX-2 mRNA expression in HMEC-1 (Fig. 1C).
3.2. Western Blot analysis of COX-2 in HMEC-1 incubated
with OSM
COX-2 protein was not detected in the absence of cytokine.
However, when the cells were incubated for 24 h with IL-1L
or OSM, COX-2 expression was stimulated. A band of 70
kDa was detected using speci¢c anti-COX-2 antibodies (Fig.
1D). A protein of approximately 45 kDa was also detected
but its expression did not change with treatment. This band
was also observed by Bishop-Bailey et al. in vascular smooth
muscle cells using another polyclonal antibody [11].
3.3. Induction of COX-2 mRNA in HUVECs
As OSM induces a signi¢cant increase in COX-2 mRNA
expression in HMEC-1, we investigated whether such an in-
crease could also be observed in macrovascular ECs. Results
in Fig. 2 show that 25 ng/ml bFGF and 5 ng/ml IL-1L in-
duced a net increase in COX-2 mRNA expression while OSM
(2.5 ng/ml) only induced a poor increase and LIF (25 ng/ml)
or IL-6 (10 ng/ml) were ine¡ective.
3.4. Non-steroidal anti-in£ammatory drugs inhibit
OSM-induced proliferation of HMEC-1
The e¡ects of COX inhibitors were evaluated on HMEC-1
proliferation induced by 2.5 ng/ml OSM.
Aspirin incubated for 5 days at concentrations ranging
from 55 WM to 2.78 mM (which did not modify the culture
medium pH) induced a decrease in cell proliferation in the
absence or in the presence of OSM (data not shown). This
decrease in the number of cells compared with the control is
due to a loss of cell viability as observed by Trypan blue
incorporation.
We then used ibuprofen, which is known to inhibit both
COX-1 and COX-2 and NS-398, a speci¢c inhibitor of COX-
2.
Co-incubation of 2.5 ng/ml OSM with ibuprofen (1^500
WM) for 5 days showed a dose-dependent decrease in OSM-
induced proliferation, reaching a plateau at 300 WM ibuprofen
(Fig. 3A). In contrast, in the absence of OSM, HMEC-1 pro-
liferation was not a¡ected by ibuprofen.
The e¡ect was more pronounced with NS-398 (0.1^100
WM), as we observed a dose-dependent inhibition of OSM-
induced proliferation reaching a plateau at 50 WM (Fig. 3B).
We also evaluated whether NS-398 (50 WM) could modify
the increase in cell proliferation induced by LIF, IL-1L or
bFGF. Fig. 3C shows that COX-2 inhibition totally prevented
IL-1L- or LIF-induced HMEC-1 proliferation and inhibited
up to 70% of bFGF-induced proliferation.
3.5. E¡ect of NS-398 on OSM-induced HMEC-1 migration
As OSM is a chemoattractant for HMEC-1, we analyzed
the e¡ect of NS-398 on OSM-induced migration. The chemo-
Fig. 2. E¡ects of 3 h incubation of HUVECs with OSM, LIF, IL-6,
bFGF or IL-1L on COX-2 mRNA expression. 1: control, 2: OSM
2.5 ng/ml, 3: LIF 25 ng/ml, 4: IL-6 10 ng/ml, 5: bFGF 25 ng/ml,
6: IL-1L 5 ng/ml.
Fig. 3. E¡ects of COX-2 inhibitors on OSM-, LIF-, IL-1L- and
bFGF-induced HMEC-1 proliferation. (A) and (B) 50U103 HMEC-
1 cells/well were seeded in a 24 well plate and incubated with in-
creasing concentrations of ibuprofen (A) or NS-398 (B) in the pres-
ence (closed square) or in the absence (open circle) of 2.5 ng/ml
OSM. At day 5, cells were detached by trypsin and then counted
with a hemocytometer. Results of ¢ve experiments in duplicate are
expressed as the ratio of the number of cells counted over the num-
ber of cells counted in the control þ S.E.M. (*P6 0.05, **P6 0.005
as compared with OSM-treated cells, n = 5). (C) Cells were seeded
as in (A) and incubated with 25 ng/ml LIF, 5 ng/ml IL-1L or 25
ng/ml bFGF in the absence or the presence of 50 WM NS-398 and
then counted after a 5 day incubation. Results of ¢ve experiments
in duplicate are expressed as the ratio of the number of cells
counted over the number of cells counted in the control þ S.E.M.
(**P6 0.005, ***P6 0.001 as compared with control cells,
‡P6 0.05, ‡‡‡P6 0.001 as compared with NS-398-untreated cells,
n = 5).
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attractant property of OSM was tested in the Transwell sys-
tem with an 8 Wm pore diameter membrane. A 24 h incuba-
tion of HMEC-1 with 2.5 ng/ml OSM induced a signi¢cant
increase in migration as compared with control, which was
partially inhibited by 50 WM NS-398 (2.49 þ 0.03-fold the con-
trol for 2.5 ng/ml OSM alone versus 1.51 þ 0.12-fold for OSM
plus NS-398, P6 0.01, n = 4). The chemoattractant e¡ect of 25
ng/ml LIF was completely inhibited by 50 WM NS-398
(1.67 þ 0.04-fold the control for 25 ng/ml LIF alone versus
1.15 þ 0.02-fold for LIF plus NS-398, P6 0.01, n = 4).
3.6. E¡ect of COX inhibitor on OSM-induced angiogenesis in
the rabbit cornea
OSM at 100 ng/implant promoted new vessel growth proc-
essing from the limbus to the implant (score = 3 þ 0, n = 4 Fig.
4A), while a treatment with 0.03% £urbiprofen three times a
day for 7 days inhibited almost completely OSM-induced an-
giogenesis (score = 1 þ 0.5, n = 4, Fig. 4B) (P6 0.005).
4. Discussion
In a previous study, we analyzed the proliferative e¡ect of
OSM and related cytokines (LIF and IL-6) on ECs from
di¡erent origins and species [3]. OSM induced a strong pro-
liferative e¡ect on microvascular ECs (HMEC-1), which was
stronger than that induced by the two angiogenic factors used
as reference, bFGF and VEGF. Furthermore, we showed that
OSM, LIF and IL-6, when added to the lower compartment
of a modi¢ed Boyden chamber (Transwell), induced a chemo-
tactic e¡ect, as shown by increased cell migration through a
polycarbonate membrane. We therefore proposed that this
angiogenic e¡ect of OSM might be involved in the in£amma-
tory process and in progression of atherosclerosis. This was
supported by the presence of activated monocytes/macro-
phages in an advanced lesion of atherosclerosis. The aim of
the present work was to identify possible molecular e¡ector(s)
of this OSM e¡ect on angiogenesis which could be involved in
atherosclerotic plaque fragilization.
Among the mechanisms involved in OSM-induced EC pro-
liferation, we further observed that OSM stimulates slightly
the secretion of VEGF on HMEC-1, VEGF is known to in-
duce proliferation of ECs. However, as a neutralizing VEGF
antibody only inhibited partially its proliferative e¡ect, we
assumed that the proliferative e¡ect of OSM is not totally
due to the secretion of VEGF [3].
In this work, we demonstrate that OSM markedly induces
COX-2 expression in HMEC-1. COX-2 mRNA expression in
HMEC-1 was increased after 3 h of incubation with OSM and
remained increased after 24 h, leading to a sustained expres-
sion of COX-2 in HMEC-1. The increase in COX-2 mRNA
was accompanied by a concomitant expression of COX-2 pro-
tein after 24 h to the same extent as induced by IL-1L.
In a previous study, we have shown that the angiogenic
e¡ect of OSM and LIF was speci¢c for microvascular ECs
and was not observed on macrovascular ECs, HUVECs. The
fact that neither OSM nor LIF induced COX-2 mRNA in
HUVECs suggested that COX-2 might mediate the angiogenic
activity of OSM.
Inhibitors of COX-2 (ibuprofen, NS-398) totally inhibit
OSM and LIF proliferative e¡ects on microvascular ECs,
supporting our hypothesis that COX-2 is a critical regulatory
molecule for OSM- and LIF-induced angiogenesis.
Therefore, OSM and LIF induced angiogenesis activity by a
mechanism similar to that of bFGF, the in vivo and in vitro
activity of which have been demonstrated to be COX-2-de-
pendent [6,12]. On HMEC-1 cells, we also showed an inhib-
itory e¡ect of NS-398 on bFGF-induced proliferation, as ob-
served with LIF and OSM. Thus, microvascular ECs produce
COX-2 in response to OSM, LIF or bFGF, which appears to
be responsible for angiogenic activity of these molecules. In a
rabbit corneal pocket model, we also demonstrated the role of
COX in OSM-induced angiogenesis as the formation of neo-
vessels was totally inhibited by local administration or £urbi-
profen. Our ¢ndings showing the role of COX-2 in angiogen-
esis are di¡erent from those of Tsujii et al. [5]. These authors
employed an EC/colon carcinoma cell co-culture model to
explore the role of COX-2 in angiogenesis. They showed
that COX-2 activity in colon carcinoma promotes angiogene-
sis by production of angiogenic factors, including bFGF and
VEGF. Nevertheless, they did not ¢nd any COX-2 production
in the ECs. In this model, they used HUVECs, which in our
hands produce COX-2 in response to bFGF. However, as
these authors used a co-culture model, other factors secreted
by cancer cells could explain this discrepancy. They observed
an increase in TGF-L1, which is known to decrease EC pro-
liferation in vitro [13].
Fig. 4. Photographs of rabbit cornea with an implant containing OSM at 100 ng/implant (A) or OSM at 100 ng/implant+£urbiprofen treatment
(B), 7 days after implantation (P: implant).
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IL-1L, which is one of the most potent inducers of COX-2
expression, induced only a poor proliferative e¡ect on
HMEC-1, as shown in Fig. 3. This suggest that COX-2 is
required for but is not su⁄cient to promote proliferation.
This is not yet explained, but it is already shown that COX-
2 products need to cooperate with other mediators such as
iNOS in the in£ammatory response [14].
In conclusion, PG products of COX-2 are important angio-
genic factors downstream of other angiogenic factors, because
both OSM and LIF, as well as bFGF, could up-regulate
COX-2 expression and, in consequence, induce angiogenesis
by promoting EC proliferation and migration.
Our results underline the fact that the inhibition of COX-2
activity could be a major therapeutic strategy to limit angio-
genesis and, by consequence, the diseases in which angiogen-
esis is a key process, such as atherosclerosis, chronic in£am-
mation and cancer.
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